Abeona Therapeutics announced an expansion to its gene therapy clinical trials for patients with MPS IIIA in the US, Europe, and Australia.
Fortress Biotech announced the creation of a new subsidiary called Aevitas Therapeutics.
AVEO Pharmaceuticals, Staar Surgical, Vericel, PDL BioPharma, Natural Alternatives top the NASDAQ biotech stock list.
Cogentix Medical, Molecular Templates, Celldex Therapeutics, Cerus and Kura Oncology top the NASDAQ biotech stock list.
uniQure will regain the rights for their hemophilia B gene therapy as the Chiesi Group backs out from working partnership with the genetics company.
Doug Casey, Brent Cook, Adrian Day, Matt Badiali, Keith Fitz-Gerald, Chris Gaffney and Byron King discuss their investment ideas and top stock picks for 2017.
uniQure N.V. entered an agreement with Chiesi Group to reacquire the rights to co-develop and commercialize its hemophilia B gene therapy in Europe.
Abeona Therapeutics appointed Dr. Juan Ruiz as the company’s chief medical officer.
Novavax, Agenus, Sierra Oncology, Durect and Cogentix top the NASDAQ biotech stock list.
Rennova decided to spin off its genetic division and create a brand new, publicly traded company, INN interviews the CEO of this game changing genetic testing company.
Abeona Therapeutics is on the path to speed up its EB-101 gene therapy interventional study to a Phase 3 clinical trial.
PreveCeutical Medical announced it entered into a research and option agreement with UniQuest to research the development of Smart-siRNAs for the treatment of diabetes and obesity.
MEI Pharma, AVEO Pharmaceuticals, Albireo Pharma, Athersys and CASI Pharmaceuticals top the list.
ZIOPHARM Oncology began enrollment for its Phase 1 study of Ad-RTS-hIL-12 and veledimex, a gene therapy for controlled expression of IL-12, in patients with recurrent glioblastoma multiforme.
AVEO, leads the list of last week’s life science gainers on the NASDAQ, followed by BioDelivery Sciences, Dynavax, Catalyst and Ekso Bionics.